News from argos therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 07, 2014, 06:00 ET

Argos Therapeutics Prices Initial Public Offering

 Argos Therapeutics, Inc. today announced the pricing of its initial public offering of 5,625,000 shares of common stock at a public offering...

Jan 28, 2014, 09:00 ET

Argos Therapeutics To Present Progress Update On Adapt Phase 3 Trial With AGS-003 At 2014 Genitourinary Cancers Symposium

 Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies...

Nov 20, 2013, 09:07 ET

Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million

 Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies...

Nov 12, 2013, 14:00 ET

Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting

Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...

Nov 11, 2013, 09:00 ET

Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma

 Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies...

May 08, 2013, 09:00 ET

Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response

Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...

Jan 15, 2013, 08:00 ET

Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study

Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...

May 03, 2012, 10:00 ET

Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks

Argos Therapeutics Inc. today announced that study results demonstrated that analytical treatment interruption to assess the antiviral activity of...

Apr 24, 2012, 08:00 ET

Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012

Argos Therapeutics Inc. today announced that it has secured a $25 million Series D financing to support the commencement of its Phase 3 ADAPT study...

Feb 04, 2012, 17:30 ET
Jan 31, 2012, 08:00 ET
Oct 04, 2011, 10:44 ET

Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System

Argos Therapeutics, Inc. today announced that its late scientific co-founder and scientific advisor Ralph M. Steinman, M.D., was awarded the Nobel...

Jul 29, 2011, 12:21 ET

Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering

Argos Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission...

Jun 28, 2011, 08:00 ET

Argos Therapeutics to Participate in Panel Discussion on Innovative Approaches to HIV Vaccine Development and Immunotherapies at 2011 BIO International Convention

Argos Therapeutics today announced that Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and...

Jun 05, 2011, 11:00 ET

Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis™ Immunotherapy AGS-003 in Combination with sunitinib Improves Progression-Free Survival (PFS) in Patients with Advanced Renal Cell Carcinoma (RCC)

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis™ immunotherapy for the treatment of renal...

Jun 01, 2011, 08:00 ET

Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes

Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination...

May 04, 2011, 08:00 ET

Argos Therapeutics' Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation

Argos Therapeutics today announced that its immunotherapy platform based on recombinant human soluble CD83 demonstrated significant promise for...

Apr 05, 2011, 08:00 ET

Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Needham & Company 10th Annual Healthcare Conference and Leerink Swann Cancer Roundtable Conference

Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present a corporate overview and the...

Mar 02, 2011, 16:05 ET

Argos Therapeutics' Arcelis™ Immunotherapy for Treatment of HIV Demonstrates Positive Outcomes in Viral Load Control and Favorable Safety and Immunogenicity Profile in Final Analysis of Phase 2a Study

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the...

Jan 31, 2011, 08:00 ET

Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial

Argos Therapeutics announced today that interleukin (IL)-12 secretion can predict the potency of the company's Arcelis™ dendritic cell (DC)...